ICN is a research-based global pharmaceutical company that manufactures, markets and distributes a broad range of prescription and non-prescription pharmaceuticals under the ICN brand name. ICN has operations in North and Latin America, Western, Central and Eastern Europe and the Pacific Rim countries. 
ICN receives royalties from the license of ribavirin, discovered and developed by ICN and licensed to and marketed by Schering-Plough Corp. (NYSE:SGP) as Rebetol® in conjunction with Schering-Plough’s Intron® A for hepatitis C. Rebetron™ is sold in the U.S. and Rebetol® in European countries. An estimated two- percent of the world“s population is infected with the hepatitis C virus. 
ICN’s research and development program focuses on anti-infectives, with emphasis on antivirals; oncology; dermatology; central nervous system compounds and pain management. Ribavirin is a product of ICN innovation. The company’s science and technology platform is based on longstanding expertise in nucleic acid chemistry. ICN has one of the largest libraries of nucleosides (components of DNA) in the pharmaceutical industry.